Drug intelligence / Profile preview

AB192

Development stage: Preclinical
Modality: Small Molecules

Overview

AB192 is an investigational drug that has been studied for the treatment of type 2 diabetes mellitus. It is associated with the class of dipeptidyl-peptidases and tripeptidyl-peptidases, enzymes involved in peptide metabolism. The specific mechanism of action, molecular structure, and detailed pharmacological profile are not publicly disclosed. There is no evidence that AB192 has reached advanced clinical development or approval stages[1][2].

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on AB192.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB192.

Explore the full profile